| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9814751 | AZURITY | Lisinopril formulations |
Nov, 2035
(12 years from now) | |
| US9616096 | AZURITY | Lisinopril formulations |
Nov, 2035
(12 years from now) | |
| US10039800 | AZURITY | Lisinopril formulations |
Nov, 2035
(12 years from now) | |
| US10406199 | AZURITY | Lisinopril formulations |
Nov, 2035
(12 years from now) | |
| US9463183 | AZURITY | Lisinopril formulations |
Nov, 2035
(12 years from now) | |
| US11179434 | AZURITY | Lisinopril formulations |
Nov, 2035
(12 years from now) | |
| US10940177 | AZURITY | Lisinopril formulations |
Nov, 2035
(12 years from now) | |
| US10265370 | AZURITY | Lisinopril formulations |
Nov, 2035
(12 years from now) | |
Qbrelis is owned by Azurity.
Qbrelis contains Lisinopril.
Qbrelis has a total of 8 drug patents out of which 0 drug patents have expired.
Qbrelis was authorised for market use on 29 July, 2016.
Qbrelis is available in solution;oral dosage forms.
Qbrelis can be used as treatment of myocardial infarction; method of treating hypertension; treatment of heart failure; method of treatment of heart failure; reduction of mortality in acute myocardial infarction; treatment of hypertension; acute myocardial infarction, acute myocardial infarction; treatment of myocardial infarction; reduction of mortality in acute myocardial infarction; method of treatment of heart failure; treatment of heart failure; treatment of hypertension; method of treating hypertension, treatment of hypertension; method of treating hypertension; treatment of heart failure; treatment of myocardial infarction; reduction of mortality in acute myocardial infarction; acute myocardial infarction; method of treatment of heart failure.
The generics of Qbrelis are possible to be released after 06 November, 2035.
Drugs and Companies using LISINOPRIL ingredient
Market Authorisation Date: 29 July, 2016
Treatment: Treatment of hypertension; Method of treating hypertension; Treatment of heart failure; Treatment of myocardial infarction; Reduction of mortality in acute myocardial infarction; Acute myocardial infa...
Dosage: SOLUTION;ORAL
QBRELIS family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic